Skip to main content
Alkem Laboratories Limited logo

Alkem Laboratories Limited — Investor Relations & Filings

Ticker · ALKEM ISIN · INE540L01014 LEI · 335800GCAE5WIF4PSG69 BSE.NS Manufacturing
Open in API
Filings indexed 1,788 across all filing types
Latest filing 2026-01-23 Regulatory Filings
Country IN India
Listing BSE.NS ALKEM

About Alkem Laboratories Limited

https://www.alkemlabs.com/

Alkem Laboratories Limited specializes in the development, manufacturing, and marketing of pharmaceutical and nutraceutical products. The company’s portfolio covers a wide range of therapeutic areas, including anti-infectives, gastrointestinal, pain management, and vitamins, minerals, and nutrients. It has also expanded into chronic therapeutic segments such as cardiology, diabetology, neurology, and dermatology. Alkem operates multiple manufacturing facilities and advanced research and development centers dedicated to formulation development and active pharmaceutical ingredients. The company provides branded generics, generic medications, and active pharmaceutical ingredients to various international markets. Its operations are supported by a robust supply chain and a focus on high-quality production standards to meet global regulatory requirements.

Recent filings

Filing Released Lang Actions
With reference to relevant provisions of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we write to inform you that a conference call to discuss the Q3 and 9MFY26 ....
Regulatory Filings
2026-01-23 English
Analysts/Institutional Investor Meet/Con. Call Updates
Call Transcript Classification · 95% confidence The document is an intimation letter to stock exchanges about a scheduled conference call to discuss the Q3FY26 and 9MFY26 financial results. It references the SEBI Listing Obligations and Disclosure Requirements Regulations, 2015, indicating regulatory compliance. The document does not contain any financial data or results itself but announces the timing and details of the conference call where such results will be discussed. The document length is 4021 characters, which is relatively short and consistent with an announcement rather than a full report or transcript. Therefore, this document is best classified as a Call Transcript (CT) announcement, but since it is only an intimation of the call and not the transcript itself, it fits the category of Regulatory Filings (RNS) as a general regulatory announcement. However, given the specific nature of the announcement about the conference call on financial results, the most precise classification is Call Transcript (CT) as it is directly related to the conference call event. Confidence is high due to clear references to the conference call and financial results discussion.
2026-01-23 English
Board Meeting — Board Meeting Intimation
Regulatory Filings
2026-01-23 English
Alkem Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/02/2026 ,inter alia, to consider and approve (i) the Standalone and Consolidated ...
Regulatory Filings
2026-01-23 English
Board Meeting — Financial Results/Dividend
Capital/Financing Update Classification · 95% confidence The document is a formal notice addressed to stock exchanges about an upcoming Board of Directors meeting scheduled for 13th February 2026. The agenda includes approval of unaudited financial results for the quarter and nine months ended 31st December 2025, and consideration of an interim dividend for the financial year 2025-2026. The document also mentions the record date for the interim dividend payment. The document is short (1535 characters) and serves as an announcement of a future event and potential financial results, not the results themselves. It does not contain actual financial data or detailed financial statements. Therefore, it is an announcement related to capital distribution (interim dividend) and financial results approval, fitting best under Capital/Financing Update (CAP).
2026-01-23 English
Please find attached herewith disclosure in respect of order passed by the Statutory Authority.
Regulatory Filings
2026-01-22 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.